How ART Transformed HIV Care
Antiretroviral therapy (ART) changed everything. Once a death sentence, HIV is now a manageable chronic condition. Millions of people on ART live long, productive lives. However, this success has created a new and urgent challenge: aging with HIV.
ART suppresses HIV replication and prevents progression to AIDS. Yet, it does not restore damaged immune function or replace depleted immune cells. As a result, many people with well-controlled HIV still carry chronic inflammation and immune dysfunction. These factors make them significantly more vulnerable to cardiovascular disease, cancer, diabetes, neurocognitive disorders, and other serious conditions.
Moreover, long-term ART use itself may raise the risk of certain comorbidities. Older drug formulations — particularly protease inhibitors from the early 2000s — can harm kidney function. Thus, the very treatment that extends life may, over time, contribute to new health problems.
High Comorbidity Risk in Aging HIV Patients
The Scale of the Problem
The comorbidity burden among aging people with HIV is substantial. One study found that approximately 71% of HIV patients developed at least one comorbidity after age 50. Furthermore, patients over 75 had a median of three comorbidities. These are striking numbers that demand clinical attention.
Cardiovascular and Neurological Risks
Compared to the general population, HIV-positive individuals are twice as likely to develop cardiovascular disease. Additionally, a review of medical records in Malawi found a dementia rate of 22% among HIV-positive individuals — double the 10% rate seen in HIV-negative individuals. Therefore, the cognitive and cardiovascular toll of aging with HIV is clearly significant.
Why Immune Dysfunction Persists
Even when ART achieves full viral suppression, chronic systemic inflammation can persist. This ongoing inflammation accelerates age-related conditions. Consequently, some researchers now believe that starting ART early — once thought to prevent immune damage — may not fully protect all patients from long-term immune dysfunction.
Research Gaps for HIV-Positive Populations
Exclusion from Clinical Trials
Many clinical trials routinely exclude people with HIV. This exclusion often stems from outdated assumptions about poor outcomes — assumptions formed before modern ART existed. However, this practice leaves critical gaps in safety and efficacy data for a large and growing patient population.
The COVID-19 vaccine offers a clear example. Early trials excluded HIV-positive individuals. A subsequent meta-analysis showed that the vaccine was safe for this group, but the initial dose produced lower immune responses. Only the booster dose offered comparable protection. This finding underscores why including people with HIV in research matters enormously.
Promising Findings Already Emerging
Where researchers have included HIV-positive patients, results have been illuminating. For instance, statin therapy — typically used to lower cholesterol and reduce major cardiovascular events — showed even greater benefit in HIV-positive populations than expected. Researchers discovered statins may also stabilize atherosclerotic plaques through collagen pathways, opening new treatment possibilities.
Similarly, GLP-1 therapies such as semaglutide show promise. Studies suggest these drugs reduce inflammation markers in people with HIV, building on evidence of their anti-inflammatory effects in other populations.
The Case for Including HIV Patients in Trials
Setting Meaningful Eligibility Criteria
Drug developers must stop relying on outdated exclusion criteria. Instead, trials should adopt HIV-specific eligibility standards, such as minimum CD4+ T cell counts, detectable or undetectable viral load thresholds, and confirmed clinical stability on ART. These criteria ensure objective evaluation without default exclusion.
Accounting for Drug Interactions
Trial designs must also address how ART interacts with investigational therapies. In some oncology trials, for example, continuing ART could compromise drug dosing or complicate toxicity management. In those cases, participants may need to switch to an alternative ART regimen temporarily. Therefore, careful protocol design is essential for safe and valid results.
The Path to Integrated HIV Care
ART has fundamentally changed the outlook for people aging with HIV. However, the healthcare system has not fully kept pace. Most comorbidity care models were not designed with HIV patients in mind. This gap represents both a serious clinical problem and a clear opportunity for drug developers.
Addressing the full spectrum of health needs in aging HIV patients requires interdisciplinary care. Clinicians, researchers, and developers must work beyond siloed medicine. Together, they need to build treatment models that account for immune dysfunction, chronic inflammation, polypharmacy risks, and the unique physiology of this population.
Ultimately, meaningful progress means treating not just the virus, but every system it affects. The next generation of HIV care must be integrated, evidence-based, and designed around the real and complex needs of people aging with HIV.
